Related references
Note: Only part of the references are listed.Dose-Dependent Activity of Pyrazinamide in Animal Models of Intracellular and Extracellular Tuberculosis Infections
Zahoor Ahmad et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
The challenge of new drug discovery for tuberculosis
Anil Koul et al.
NATURE (2011)
Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections
Julian G. Hurdle et al.
NATURE REVIEWS MICROBIOLOGY (2011)
Probing the Interaction of the Diarylquinoline TMC207 with Its Target Mycobacterial ATP Synthase
Anna C. Haagsma et al.
PLOS ONE (2011)
Respiratory ATP synthesis: the new generation of mycobacterial drug targets?
Dirk Bald et al.
FEMS MICROBIOLOGY LETTERS (2010)
ATP synthase in slow- and fast-growing mycobacteria is active in ATP synthesis and blocked in ATP hydrolysis direction
Anna C. Haagsma et al.
FEMS MICROBIOLOGY LETTERS (2010)
Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis
Neel R. Gandhi et al.
LANCET (2010)
How antibiotics kill bacteria: from targets to networks
Michael A. Kohanski et al.
NATURE REVIEWS MICROBIOLOGY (2010)
A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy
Kevin Pethe et al.
NATURE COMMUNICATIONS (2010)
Selectivity of TMC207 towards Mycobacterial ATP Synthase Compared with That towards the Eukaryotic Homologue
Anna C. Haagsma et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Andreas H. Diacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis
R. Rustomjee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis
Anil Koul et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis
Srinivasa P. S. Rao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Inhibition of isolated mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs
Silvana C. Ngo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Diarylquinolines target subunit c of mycobacterial ATP synthase
Anil Koul et al.
NATURE CHEMICAL BIOLOGY (2007)
Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis
Qiang Huang et al.
CHEMOTHERAPY (2007)
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis
K Andries et al.
SCIENCE (2005)
Iron enhances the antituberculous activity of pyrazinamide
A Somoskovi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis
MM Wade et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2004)
Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid
Y Zhang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I
HI Boshoff et al.
JOURNAL OF BACTERIOLOGY (2002)
Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide
Y Zhang et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2002)
Intracellular pH regulation by Mycobacterium smegmatis and Mycobacterium bovis BCG
M Rao et al.
MICROBIOLOGY-UK (2001)
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis
O Zimhony et al.
NATURE MEDICINE (2000)